/BIOVF

BIOVF Stock - Swedish Orphan Biovitrum AB (publ)

Q: What is the analyst price target for BIOVF?

Analyst price target information is not currently available for BIOVF.

Q: What is BIOVF's market cap?

Market capitalization information is not currently available for BIOVF.

Healthcare|Drug Manufacturers - Specialty & Generic|OTC

$35.25+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $38.78

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BIOVF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.19

52W High$35.26

52W Low$25.80

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$26.03B	$22.12B	$18.79B	$15.53B	$15.26B
Gross Profit	$20.24B	$17.13B	$14.01B	$12.04B	$12.04B
Gross Margin	77.8%	77.4%	74.6%	77.6%	78.9%
Operating Income	$5.63B	$4.07B	$3.81B	$3.73B	$4.82B
Net Income	$3.88B	$2.41B	$2.64B	$2.68B	$3.25B
Net Margin	14.9%	10.9%	14.0%	17.3%	21.3%
EPS	$11.37	$7.39	$8.52	$8.67	$10.52

Company Overview

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

Visit Website

Earnings History & Surprises

BIOVF

Beat Rate

83%

Last 18 quarters

Avg Surprise

+20.5%

EPS vs Estimate

Beats / Misses

15/3

Last 12 quarters

Latest EPS

$0.64

Q4 2025

EPS Surprise History

Q1 24

-46.4%

$0.30vs$0.56

Q2 24

+18.8%

$0.26vs$0.22

Q3 24

-2.5%

$0.07vs$0.07

Q4 24

+84.8%

$0.40vs$0.22

Q1 25

+14.4%

$0.37vs$0.32

Q2 25

+20.8%

$0.26vs$0.22

Q3 25

+35.6%

$0.24vs$0.18

Q4 25

+29.9%

$0.64vs$0.49

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	Apr 27, 2026	—	—	—	—
Q1 2026	Feb 3, 2026	—	—	—	—
Q4 2025	Oct 20, 2025	$0.49	$0.64	+29.9%	✓ BEAT
Q3 2025	Jul 16, 2025	$0.18	$0.24	+35.6%	✓ BEAT
Q2 2025	Apr 29, 2025	$0.22	$0.26	+20.8%	✓ BEAT
Q1 2025	Feb 5, 2025	$0.32	$0.37	+14.4%	✓ BEAT
Q4 2024	Oct 24, 2024	$0.22	$0.40	+84.8%	✓ BEAT
Q3 2024	Jul 16, 2024	$0.07	$0.07	-2.5%	✗ MISS
Q2 2024	Apr 25, 2024	$0.22	$0.26	+18.8%	✓ BEAT
Q1 2024	Feb 8, 2024	$0.56	$0.30	-46.4%	✗ MISS
Q4 2023	Oct 30, 2023	$0.09	$0.05	-44.4%	✗ MISS
Q3 2023	Jul 18, 2023	$0.11	$0.14	+27.3%	✓ BEAT
Q2 2023	Apr 27, 2023	$0.22	$0.34	+54.5%	✓ BEAT
Q1 2023	Feb 8, 2023	$0.44	$0.44	+0.2%	✓ BEAT
Q4 2022	Oct 27, 2022	$0.12	$0.14	+19.5%	✓ BEAT
Q3 2022	Jul 19, 2022	$0.06	$0.08	+38.7%	✓ BEAT
Q2 2022	Apr 28, 2022	$0.29	$0.39	+33.8%	✓ BEAT
Q1 2022	Feb 10, 2022	$0.37	$0.45	+22.6%	✓ BEAT
Q4 2021	Oct 22, 2021	$0.15	$0.18	+22.3%	✓ BEAT
Q3 2021	Jul 21, 2021	$0.07	$0.10	+38.4%	✓ BEAT

Frequently Asked Questions about BIOVF

What is BIOVF's current stock price?

Swedish Orphan Biovitrum AB (publ) (BIOVF) is currently trading at $35.25 per share. The stock has moved +0.00% today.

What is the analyst price target for BIOVF?

No analyst price targets are currently available for this stock.

What sector is Swedish Orphan Biovitrum AB (publ) in?

Swedish Orphan Biovitrum AB (publ) operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the OTC exchange.

What is BIOVF's market cap?

Swedish Orphan Biovitrum AB (publ) has a market capitalization of $12.15 billion, making it a large-cap company.

Does BIOVF pay dividends?

No, Swedish Orphan Biovitrum AB (publ) does not currently pay a dividend to shareholders.